KR890014110A - Medication - Google Patents

Medication Download PDF

Info

Publication number
KR890014110A
KR890014110A KR1019890002612A KR890002612A KR890014110A KR 890014110 A KR890014110 A KR 890014110A KR 1019890002612 A KR1019890002612 A KR 1019890002612A KR 890002612 A KR890002612 A KR 890002612A KR 890014110 A KR890014110 A KR 890014110A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
therapeutic agent
inflammatory agent
supotidine
free base
Prior art date
Application number
KR1019890002612A
Other languages
Korean (ko)
Inventor
스테이블스 로저
토마스 번스 케이쓰
Original Assignee
원본 미기재
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본 미기재, 글락소 그룹 리미티드 filed Critical 원본 미기재
Publication of KR890014110A publication Critical patent/KR890014110A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음.No content.

Description

의약제Medication

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (19)

비(非)스테로이드계 전신 소염제 및 수포티딘 또는 생리학적으로 허용되는 그의 염으로 구성됨을 특징으로 하는 사람 또는 가축 의약제용 제약 소성물.A pharmaceutical calcined product for human or domestic pharmaceuticals, comprising a nonsteroidal systemic anti-inflammatory agent and supotidine or a physiologically acceptable salt thereof. 제1항에 있어서, 수포티딘이 유리 염기 형태, 또는 염산염, 브롬화수소산염, 황산염, 메탄술폰산염, 아세트산염, 말레산염, 숙신산염, 타르타르산염, 벤조산염 또는 푸마르산염으로서 사용되는 제약 조성물.The pharmaceutical composition according to claim 1, wherein the supotididine is used in free base form, or as hydrochloride, hydrobromide, sulfate, methanesulfonate, acetate, maleate, succinate, tartarate, benzoate or fumarate. 제2항에 있어서, 수포티딘이 유리 염기 형태로 사용되는 제약 조성물.The pharmaceutical composition of claim 2, wherein the supotididine is used in the free base form. 제1항 내지 3항중 어느 하나의 항에 있어서, 수포티딘을 유리 염기 중량으로서 단위 투여량 당 50 내지 600mg 함유하는 단위 투여 형태의 제약 조성물.The pharmaceutical composition according to any one of claims 1 to 3, which contains 50 to 600 mg per unit dose of supotidine as the free base weight. 제1 내지 4항중 어느 하나의 항에 있어서, 비스테로이드계 소염제가 아스피린, 인도메타신, 이부프로펜, 피록시캄, 페노프로펜, 케토프로펜, 나프록센, 메페남산, 디플루니살 베노릴레이트 아자프로파존, 디클로페낙, 펜부펜, 페프라존 펜클로페낙, 플루페남산, 플루르비프로펜, 옥시펜부타존, 페닐부타존, 술린닥 및 톨메틴에서 선택되는 제약 조성물.The nonsteroidal anti-inflammatory agent according to any one of claims 1 to 4, wherein the non-steroidal anti-inflammatory agent is aspirin, indomethacin, ibuprofen, pyroxicam, phenopropene, ketoprofen, naproxen, mefenamic acid, diflunisal benolate aza A pharmaceutical composition selected from propazone, diclofenac, fenbufen, peprazone fenclofenac, flufenamic acid, flurbiprofen, oxyfenbutazone, phenylbutazone, sulindac and tolmetin. 제5항에 있어서, 비스테로이드계 소염제가 피록시캄인 제약 조성물.The pharmaceutical composition according to claim 5, wherein the nonsteroidal anti-inflammatory agent is pyroxicam. 제6항에 있어서 단위 투여량 당 피록시캄 5-50mg을 함유하는 단위 투여 형태의 제약 조성물.The pharmaceutical composition of claim 6, wherein the unit dosage form contains 5-50 mg of pyroxycam per unit dose. 제1 내지 7항 중 어느 하나의 항에 있어서, 경구 투여에 적합한 형태의 제약 조성물.The pharmaceutical composition according to any one of claims 1 to 7, in a form suitable for oral administration. 제1 내지 8항 중 어느 하나의 항에 있어서, 제약상 허용되는 적어도 1종의 담체 또는 부형제를 함유하는 제약 조성물.The pharmaceutical composition according to any one of claims 1 to 8, which contains at least one pharmaceutically acceptable carrier or excipient. 구성 성분들을 통상적인 방법으로 제약 조성물로 가공함을 특징으로 하는 제1 내지 9항 어느 하나의 항에 의한 제약 조성물의 제조 방법.Process for the preparation of a pharmaceutical composition according to any one of claims 1 to 9, characterized in that the components are processed into a pharmaceutical composition in a conventional manner. 염증을 치료하기 위항 비스테로이드계 전신 소염제를 함께 투여하는 사람 또는 가축용 의약제에 있어서, 의약제가 수포티딘 또는 생리학적으로 허용되는 그의 염으로 구성됨을 특징으로 하는 치료제.A pharmaceutical for humans or domestic animals administered together with a nonsteroidal systemic anti-inflammatory agent to treat inflammation, characterized in that the medicament consists of supotidine or a physiologically acceptable salt thereof. 제11항에 있어서, 수포티딘에 유리 염기 형태, 또는 염산염, 브롬화수소산염, 황산염, 메탄술폰산염, 아세트산염, 말레산염, 숙신산염, 타르타르산염, 벤조산염 또는 푸마르산염으로서 사용되는 치료제.The therapeutic agent according to claim 11, which is used in the supotidine in free base form, or as hydrochloride, hydrobromide, sulfate, methanesulfonate, acetate, maleate, succinate, tartarate, benzoate or fumarate. 제12항에 있어서, 수포티딘이 유리 염기 형태로 사용되는 치료제.13. The therapeutic agent according to claim 12, wherein the supotidine is used in the free base form. 제11 내지 13항 중 어느 하나의 항에 있어서, 수포티딘을 유리 염기 중량으로서 단위 투여량 당 50 내지 600mg 함유하는 단위 투여 형태의 치료제.The therapeutic agent of any one of claims 11 to 13, wherein the therapeutic agent contains 50 to 600 mg per unit dose of supotidine as the free base weight. 제11 내지 14항 중 어느 하나의 항에 있어서, 비스테로이드계 소염제가 아스피린, 인도메타신, 이부프로펜, 피록시캄, 페노프로펜, 케토프로펜, 나프록센, 메페남산, 디플루니살, 베노릴레이트, 아자프로파존, 디클로페낙, 펜부펜, 페프라존, 펜클로페낙, 플루페남산, 플루르비프로펜, 옥시펜부타존, 페닐부타존 술린닥 및 톨메틴에서 선택되는 치료제.15. The nonsteroidal anti-inflammatory agent according to any one of claims 11 to 14, wherein the nonsteroidal anti-inflammatory agent is aspirin, indomethacin, ibuprofen, pyroxicam, phenopropene, ketoprofen, naproxen, mefenamic acid, diflunisal, benorelay Therapeutic agent selected from lute, azapropazone, diclofenac, fenbufen, peprazone, fenclofenac, flufenamic acid, flurbiprofen, oxyfenbutazone, phenylbutazone sulindac and tolmetin. 제15항에 있어서, 비스테로이드계 소염제가 피록시캄인 치료제.The therapeutic agent according to claim 15, wherein the nonsteroidal anti-inflammatory agent is pyroxicam. 제16항에 있어서, 피록시캄이 단위 투여량 당 피록시캄 5-50mg을 함유하는 단위투여 형태로 사용되는 치료제.17. The therapeutic agent according to claim 16, wherein the phyroxicam is used in unit dosage form containing 5-50 mg of phyroxicam per unit dose. 제11 내지 17항 중 어느 하나의 항에 있어서, 경구 투여에 적합한 형태의 치료제.18. A therapeutic agent according to any one of claims 11 to 17 in a form suitable for oral administration. 제11 내지 18항중 어느 하나의 항에 있어서, 비스테로이드계 소염제가 분리 형태로서 함께 투여되는 치료제.The therapeutic agent according to any one of claims 11 to 18, wherein the nonsteroidal anti-inflammatory agent is administered together as a separate form. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019890002612A 1988-03-04 1989-03-03 Medication KR890014110A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8805268 1988-03-04
GB888805268A GB8805268D0 (en) 1988-03-04 1988-03-04 Medicaments

Publications (1)

Publication Number Publication Date
KR890014110A true KR890014110A (en) 1989-10-21

Family

ID=10632893

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002612A KR890014110A (en) 1988-03-04 1989-03-03 Medication

Country Status (12)

Country Link
JP (1) JP2834175B2 (en)
KR (1) KR890014110A (en)
AU (1) AU3098489A (en)
BE (1) BE1002256A3 (en)
DE (1) DE3906884A1 (en)
DK (1) DK104489A (en)
FR (1) FR2627985A1 (en)
GB (2) GB8805268D0 (en)
IT (1) IT8947714A0 (en)
NL (1) NL8900525A (en)
SE (1) SE8900752L (en)
ZA (1) ZA891640B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO300260B1 (en) 1993-05-05 1997-05-05 Torgersen Hans & Soenn Children's car seat
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
TR200200737T2 (en) * 1999-09-24 2002-08-21 Alcon, Inc. Local suspension formulations containing ciproflaxacin and dexamethasone
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
UA115139C2 (en) 2011-12-28 2017-09-25 Поузен Інк. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2477150A1 (en) * 1980-02-28 1981-09-04 Glaxo Group Ltd NOVEL HETEROCYCLIC DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
BE894286A (en) * 1981-09-04 1983-03-02 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROID SYSTEMIC ANTI-INFLAMMATORY DRUG AND 1-METHYL-5 - ((3- (3- (3- (1-PIPERIDINYLMETHYL) PHENOXY) -PROPYL) AMINO -1H-1,2,4-TRIAZOLE-3- METHANOL OR A SALT OF THIS COMPOUND
GB2105193B (en) * 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs

Also Published As

Publication number Publication date
AU3098489A (en) 1989-09-07
IT8947714A0 (en) 1989-03-03
JP2834175B2 (en) 1998-12-09
DE3906884A1 (en) 1989-09-14
BE1002256A3 (en) 1990-11-06
DK104489D0 (en) 1989-03-03
GB2216413A (en) 1989-10-11
GB8805268D0 (en) 1988-04-07
DK104489A (en) 1989-09-05
FR2627985A1 (en) 1989-09-08
ZA891640B (en) 1990-03-28
GB8904879D0 (en) 1989-04-12
NL8900525A (en) 1989-10-02
SE8900752D0 (en) 1989-03-03
JPH01316319A (en) 1989-12-21
SE8900752L (en) 1989-09-05

Similar Documents

Publication Publication Date Title
AR028299A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
RU2000123567A (en) PHARMACEUTICAL COMPOSITION, CONTAINING METFORMIN AND FIBRATES IN THE COMBINATION, AND ITS APPLICATION FOR PREPARATION OF MEDICINES, INTENDED TO REDUCE HYPERGLYCEMIA
PT100635A (en) PHARMACEUTICAL DOSE FOR THE DELAYED ADMINISTRATION OF A PHARMACO
KR930009605A (en) Anti-inflammatory or analgesic
KR930007441A (en) medicine
PT866713E (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
BR122012014331A8 (en) PHARMACEUTICAL FORMULATIONS
KR910009254A (en) Pharmaceutical compositions and methods for treating overeating and / or post-drinking symptoms
Pfaffenrath et al. Analgesics and NSAIDs in the treatment of the acute migraine attack
KR920700630A (en) Expression-promoted / enhanced antipyretic reactions
Catapano The analgesic efficacy of ketorolac for acute pain
SE466889B (en) Analgesic and anti-inflammatory compositions consisting of ibuprofen and caffeine
KR890014110A (en) Medication
JPH05500361A (en) Initiation – accelerated/enhanced antipyretic response
Lynch et al. Etodolac: a preliminary review of its pharmacodynamic activity and therapeutic use
JPH0314812B2 (en)
JP2016014064A (en) Pharmaceutical composition
KR890014109A (en) Medication
WO2004093864A1 (en) Non-steroidal anti-inflammatory drug dosing regimen
KR890007728A (en) Painkiller
JPS5921615A (en) Analgesic composition
JP2000500159A (en) Painkillers combined with melatonin
JP2011225508A (en) Loxoprofen-containing medicinal preparation
CA1141664A (en) Analgesic composition
RU2002129356A (en) COMBINATION OF MEDICINES FOR TREATMENT OF HEADACHE CONTAINING A NON-STEROID ANTI-INFLAMMATORY MEDICINE

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid